Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Aug;51(8):965–968. doi: 10.1136/ard.51.8.965

Plasminogen activators in synovial fluid and plasma from patients with arthritis.

E J Brommer 1, G Dooijewaard 1, B A Dijkmans 1, F C Breedveld 1
PMCID: PMC1004805  PMID: 1417121

Abstract

The activity of plasminogen activators and inhibitors in the synovial fluid and plasma of patients with various forms of chronic arthritis was characterised. Tissue-type plasminogen activator antigen (t-PA:Ag), urokinase-type plasminogen activator antigen (u-PA:Ag), the proenzyme single chain u-PA (scu-PA), and plasminogen activator inhibitor (PAI) were measured in the synovial fluid and plasma of 22 patients with seropositive rheumatoid arthritis (RA), 13 with seronegative RA, and 23 patients with various forms of arthritis. In all patient groups the levels of t-PA:Ag in synovial fluid were lower and the levels of u-PA:Ag and PAI higher than plasma levels. Synovial fluid u-PA was more activated than plasma u-PA. Comparison of the patient groups showed that the largest differences between fibrinolytic parameters in synovial fluid and plasma were present in patients with seropositive RA followed by patients with seronegative RA and patients with various forms of arthritis. This order paralleled the functional and radiological scores of joint destruction in the patient groups studied. The results of this study indicate that suppression of t-PA production and enhancement of u-PA synthesis and activation in arthritic joints are associated with the clinical severity of arthritis.

Full text

PDF
965

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Barnhart M. I., Riddle J. M., Bluhm G. B., Quintana C. Fibrin promotion and lysis in arthritic joints. Ann Rheum Dis. 1967 May;26(3):206–218. doi: 10.1136/ard.26.3.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Belch J. J., McArdle B., Madhok R., McLaughlin K., Capell H. A., Forbes C. D., Sturrock R. D. Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Ann Rheum Dis. 1984 Dec;43(6):774–777. doi: 10.1136/ard.43.6.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Binnema D. J., van Iersel J. J., Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res. 1986 Sep 1;43(5):569–577. doi: 10.1016/0049-3848(86)90077-0. [DOI] [PubMed] [Google Scholar]
  5. Brommer E. J., Boks A. L., Koopman J., Haverkate F. Protraction of whole blood and plasma clot lysis in patients with high levels of an inhibitor of tissue-type plasminogen activator. Thromb Res. 1985 Aug 1;39(3):271–280. doi: 10.1016/0049-3848(85)90222-1. [DOI] [PubMed] [Google Scholar]
  6. Bunning R. A., Crawford A., Richardson H. J., Opdenakker G., Van Damme J., Russell R. G. Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes. Biochim Biophys Acta. 1987 Jun 22;924(3):473–482. doi: 10.1016/0304-4165(87)90163-2. [DOI] [PubMed] [Google Scholar]
  7. Butler M., Colombo C., Hickman L., O'Byrne E., Steele R., Steinetz B., Quintavalla J., Yokoyama N. A new model of osteoarthritis in rabbits. III. Evaluation of anti-osteoarthritic effects of selected drugs administered intraarticularly. Arthritis Rheum. 1983 Nov;26(11):1380–1386. doi: 10.1002/art.1780261111. [DOI] [PubMed] [Google Scholar]
  8. Collier S., Ghosh P. The role of plasminogen in interleukin-1 mediated cartilage degradation. J Rheumatol. 1988 Jul;15(7):1129–1137. [PubMed] [Google Scholar]
  9. Gurewich V., Pannell R. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood. 1987 Mar;69(3):769–772. [PubMed] [Google Scholar]
  10. Kikuchi H., Tanaka S., Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol. 1987 Jun;14(3):439–445. [PubMed] [Google Scholar]
  11. Knabb R. M., Chiu A. T., Reilly T. M. Effects of recombinant plasminogen activator inhibitor type 1 on fibrinolysis in vitro and in vivo. Thromb Res. 1990 Jul 15;59(2):309–317. doi: 10.1016/0049-3848(90)90133-w. [DOI] [PubMed] [Google Scholar]
  12. LACK C. H., ROGERS H. J. Action of plasmin on cartilage. Nature. 1958 Oct 4;182(4640):948–949. doi: 10.1038/182948a0. [DOI] [PubMed] [Google Scholar]
  13. Lindenhayn K., Heilmann H. H., Regling G., Haupt R. Die Plasminogenaktivator-Aktivität der Synovialflüssigkeit als Indikator für Aktivierungsphänomene bei degenerativen Gelenkerkrankungen. Z Rheumatol. 1989 Sep-Oct;48(5):246–253. [PubMed] [Google Scholar]
  14. Matsuo O., Tanaka S., Kikuchi H. Effect of urinary trypsin inhibitor on osteoarthritis. Thromb Res. 1988 Nov 1;52(3):237–245. doi: 10.1016/0049-3848(88)90083-7. [DOI] [PubMed] [Google Scholar]
  15. Medcalf R. L., Hamilton J. A. Human synovial fibroblasts produce urokinase-type plasminogen activator. Arthritis Rheum. 1986 Nov;29(11):1397–1401. doi: 10.1002/art.1780291113. [DOI] [PubMed] [Google Scholar]
  16. Mizel S. B., Dayer J. M., Krane S. M., Mergenhagen S. E. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A. 1981 Apr;78(4):2474–2477. doi: 10.1073/pnas.78.4.2474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mochan E., Keler T. Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta. 1984 Aug 21;800(3):312–315. doi: 10.1016/0304-4165(84)90412-4. [DOI] [PubMed] [Google Scholar]
  18. Mochan E., Uhl J. Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis. J Rheumatol. 1984 Apr;11(2):123–128. [PubMed] [Google Scholar]
  19. Otten H. G., Daha M. R., de Rooij H. H., Breedveld F. C. Quantitative detection of class-specific rheumatoid factors using mouse monoclonal antibodies and the biotin/streptavidin enhancement system. Br J Rheumatol. 1989 Aug;28(4):310–316. doi: 10.1093/rheumatology/28.4.310. [DOI] [PubMed] [Google Scholar]
  20. Philippé J., Offner F., Declerck P. J., Leroux-Roels G., Vogelaers D., Baele G., Collen D. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost. 1991 Mar 4;65(3):291–295. [PubMed] [Google Scholar]
  21. Saksela O., Hovi T., Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J Cell Physiol. 1985 Jan;122(1):125–132. doi: 10.1002/jcp.1041220119. [DOI] [PubMed] [Google Scholar]
  22. Staite N. D., Richard K. A., Aspar D. G., Franz K. A., Galinet L. A., Dunn C. J. Induction of an acute erosive monarticular arthritis in mice by interleukin-1 and methylated bovine serum albumin. Arthritis Rheum. 1990 Feb;33(2):253–260. doi: 10.1002/art.1780330215. [DOI] [PubMed] [Google Scholar]
  23. Vassalli J. D., Dayer J. M., Wohlwend A., Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med. 1984 Jun 1;159(6):1653–1668. doi: 10.1084/jem.159.6.1653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Verheijen J. H., Chang G. T., Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost. 1984 Jul 29;51(3):392–395. [PubMed] [Google Scholar]
  25. Werb Z., Mainardi C. L., Vater C. A., Harris E. D., Jr Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med. 1977 May 5;296(18):1017–1023. doi: 10.1056/NEJM197705052961801. [DOI] [PubMed] [Google Scholar]
  26. van Hinsbergh V. W., Kooistra T., Scheffer M. A., Hajo van Bockel J., van Muijen G. N. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood. 1990 Apr 1;75(7):1490–1497. [PubMed] [Google Scholar]
  27. van Hinsbergh V. W., van den Berg E. A., Fiers W., Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood. 1990 May 15;75(10):1991–1998. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES